Pharmacyclics, Inc. (PCYC) to Report Statistically Significant Data from Phase III PCYC-1112
Tweet Send to a Friend
Pharmacyclics, Inc. (Nasdaq: PCYC) announced that data from the Phase III PCYC-1112 (RESONATE™) study of single agent IMBRUVICA™ (ibrutinib) vs ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
